AstraZeneca Investor Conference Presentation Deck

Strong financials Double digit growth in Oncology, BioPharmaceuticals and Rare Disease driving earnings growth and cash generation $24.4bn FY 2019 Total Revenue $26.6bn FY 2020 $37.4bn FY 2021 $33.1bn 9M 2022 +37% Growth¹ in 9M 2022 5 1. Growth rates for Total Revenue and Core EPS are at constant exchange rate. EPS = earnings per share. $3.50 FY 2019 Core EPS $4.02 FY 2020 $5.29 FY 2021 $5.28 9M 2022 +52% Growth¹ in 9M 2022 Net Cash Flow From Operating Activities $3.0bn FY 2019 $4.8bn FY 2020 $6.0bn FY 2021 $7.4bn 9M 2022 +16% Growth in 9M 2022

View entire presentation